The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2...
Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia J Clin Oncol, 40 (35) (2022), pp. 4048-4059 CrossrefView in ScopusGoogle Scholar 78 N Short, CD DiNardo, N Daver, et al. Updated results from a phase I/II study of the triplet combination of azac...
How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005;19:497-499.Hasford J, Pfirrmann M. Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia. 2005; 19 :497–499....
How are stem cells used to treat leukemia? How does lymphocytic leukemia disrupt normal cell communication? What is chronic myeloid leukemia? How does non-Hodgkin lymphoma develop? What is a high white blood cell count for leukemia? What kind of cancer is leukemia?
How are stem cells used to treat leukemia? What happens if a patient with leukemia goes untreated? Can a child survive leukemia? What is the disease process of leukemia? Can leukemia go into remission? How long does it take to cure leukemia? How does chronic myeloid leukemia affect the body...
Acute myeloid leukemia (AML) is a malignant hematological neoplastic disease. Autocrine or paracrine cytokines released by leukemic cells regulate the prol
Acute Leukemia: This type progresses rapidly, with immature blood cells multiplying uncontrollably. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are the two main subtypes. Chronic Leukemia: This variety develops more slowly, with mature blood cells affected. Chronic myeloid leukem...
leukemia, myelocytic, acutemutationms-like tyrosine kinase 3allogeneic hematopoietic stem cell transplantdrug discoveryTreatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing...
How I treat with maintenance therapy after allogeneic HCT Blood, 141 (1) (2023), pp. 39-48 View PDFView articleCrossrefView in ScopusGoogle Scholar 27 S Loghavi, Z Zuo, F Ravandi, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutati...
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomarker Research. 2019;7(1):9. 72. Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomarker Research. 2019;7(1):24. 73...